Walmsley and GSK, with facilities in Collegeville and Valley Forge, Pa., have been under assault by activist hedge funds Elliott Management and Bluestone Capital Management, who don’t believe ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

Feb 5 (Reuters) - UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold miners, while investors turned their focus to the Bank ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...